Aytu BioPharma (NASDAQ:AYTU) Rating Increased to Strong-Buy at Wall Street Zen

Aytu BioPharma (NASDAQ:AYTU) was upgraded by equities research analysts at Wall Street Zen to a “strong-buy” rating in a note issued to investors on Friday.

Aytu BioPharma Trading Down 0.9%

NASDAQ AYTU opened at $2.10 on Friday. The firm has a market cap of $18.86 million, a P/E ratio of -2.92 and a beta of 0.05. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.03 and a quick ratio of 0.87. The stock’s 50-day moving average is $1.69 and its 200-day moving average is $1.50. Aytu BioPharma has a one year low of $0.95 and a one year high of $2.96.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings results on Wednesday, May 14th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.37. The company had revenue of $18.45 million for the quarter, compared to analyst estimates of $13.74 million. Aytu BioPharma had a return on equity of 3.51% and a net margin of 2.37%.

Institutional Investors Weigh In On Aytu BioPharma

An institutional investor recently raised its position in Aytu BioPharma stock. Stonepine Capital Management LLC boosted its position in Aytu BioPharma Inc. (NASDAQ:AYTU) by 13.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 463,721 shares of the company’s stock after buying an additional 56,172 shares during the quarter. Stonepine Capital Management LLC owned approximately 7.52% of Aytu BioPharma worth $556,000 as of its most recent filing with the SEC. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.